Funding to advance Phase 2 clinical trials of azelaprag, an apelin receptor (APJ) agonist, in combination with Lilly’s Zepbound (tirzepatide) and therapeutic pipeline Azelaprag improves metabolic and ...
First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers BGE-102 achieved 86% reduction in ...
Shares of BioAge (NASDAQ:BIOA) cratered 70% Friday in post-market trading after the company said it was discontinuing a Phase 2 study for its weight-loss drug azelaprag over safety concerns. Of the ...
BioAge Labs will analyze 17,000 samples from Norway's HUNT Biobank to enhance drug target discovery for aging-related diseases. BioAge Labs, Inc. has announced a new initiative to analyze over 17,000 ...
Shares of BioAge Labs (BIOA) continued to spike for the second consecutive session on Tuesday in reaction to updated results from an early-stage trial for the company’s lead asset, BGE-102, targeted ...
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of BioAge Labs, Inc. (NASDAQ: BIOA) stock pursuant and/or traceable to BioAge Labs’ ...
BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results